To confirm this, we treated the EGFR-TKI-resistant NSCLC cell lines A549 and H1975 with increasing concentrations of SANT-1 alone, gefitinib alone, and combinations of SANT-1 and gefitinib, and then assessed their proliferation. Here, EGFR is linked to non-small cell lung carcinoma.